Marston will oversee both MDLs in the Eastern District of Pennsylvania
Si aparece y se mantiene, una opcin es reducir la dosis o interrumpir el uso y consultar con un profesional sanitario, especialmente si se est tomando por un motivo clnico
Adults with obesity (BMI 30) or with overweight (BMI 27) plus at least one weight-related condition such as type 2 diabetes, hypertension or dyslipidaemia
In the same trial, tirzepatide and semaglutide were compared once weekly in the open-label, phase III SURPASS-2 experiment
In this study, obese men underwent an initial 8-week low-calorie diet (very low calorie, ~800 kcal/day), losing on average 16.5 kg (about 15% of body weight) pubmed.ncbi.nlm.nih.gov
Most people benefit from both